Hidden hepatitis e threat in transplant patients?
NCT ID NCT02190253
First seen Jun 25, 2026 · Last updated Sep 17, 2026 · Updated 6 times
Summary
This study checked how many organ transplant recipients in the U.S. have antibodies to the hepatitis E virus, which can become chronic in people with weakened immune systems. Researchers enrolled 447 adults who had a liver, kidney, or small bowel transplant or were on a waiting list. Participants gave a blood sample and answered questions about possible risk factors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If this study finds that hepatitis E is common in transplant patients, it could lead to better screening and care to prevent chronic infection.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures antibody levels, so it cannot show cause or predict outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
447 people
The number who actually took part.
- Started
-
Jul 2014
- Finished
-
Feb 2019
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Tertiary referral center with liver transplant program
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* ELIGIBILITY CRITERIA: Inclusion criteria for post-transplant subjects * Age greater than or equal to 18 years, male or female * Recipients of either liver, kidney, liver and kidney, and small bowel transplants * Survival for a minimum of 1 year post-transplant * Willingness to provide written, informed consent Exclusion criteria for post-transplant subjects: * Current or previous treatment within the last year with peg-interferon and or ribavirin. * Known history of hepatitis E infection. Inclusion criteria for waitlist subjects: * Age greater than or equal to 18 years, male or female * Subjects on the waitlist for first liver, kidney, liver and kidney or small bowel transplant * Willingness to provide written, informed consent Exclusion criteria for waitlist subjects: * Current or previous treatment within the last year with peg-interferon and or ribavirin. * Current immunosuppression * Known history of hepatitis E infection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hepatitis E are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Georgetown University
Washington D.C., District of Columbia, 20007-2197, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104-6056, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.